| Amine Asmerom |
CHYM |
Class A Common Stock |
Award |
17.8% |
|
|
37,524 |
248,737 |
12 Mar 2026 |
Direct |
| Amine Asmerom |
CHYM |
Employee Stock Option (Right to buy) |
Award |
|
|
|
75,048 |
75,048 |
12 Mar 2026 |
Direct |
| Adam B. Frankel |
CHYM |
Class A Common Stock |
Award |
53.7% |
|
|
112,571 |
322,233 |
12 Mar 2026 |
Direct |
| Adam B. Frankel |
CHYM |
Employee Stock Option (Right to buy) |
Award |
|
|
|
225,142 |
225,142 |
12 Mar 2026 |
Direct |
| Matthew S. Newcomb |
CHYM |
Class A Common Stock |
Award |
37.7% |
|
|
140,713 |
514,310 |
12 Mar 2026 |
Direct |
| Matthew S. Newcomb |
CHYM |
Employee Stock Option (Right to buy) |
Award |
|
|
|
281,426 |
281,426 |
12 Mar 2026 |
Direct |
| Troughton Mark T. |
CHYM |
Class A Common Stock |
Award |
7.7% |
|
|
206,379 |
2,886,106 |
12 Mar 2026 |
Direct |
| Troughton Mark T. |
CHYM |
Employee Stock Option (Right to buy) |
Award |
|
|
|
412,758 |
412,758 |
12 Mar 2026 |
Direct |
| Christopher R. Britt |
CHYM |
Employee Stock Option (Right to buy) |
Award |
|
|
|
900,563 |
900,563 |
12 Mar 2026 |
Direct |
| Ryan A. King |
CHYM |
Employee Stock Option (Right to buy) |
Award |
|
|
|
450,282 |
450,282 |
12 Mar 2026 |
Direct |
| Cynthia Marshall |
CHYM |
Class A Common Stock |
Sale |
-48.1% |
$779,674 |
$22.28 |
-35,000 |
37,795 |
02 Mar 2026 |
Direct |
| Matthew S. Newcomb |
CHYM |
Class A Common Stock |
Gift |
1.01% |
|
|
22,523 |
2,263,321 |
18 Feb 2026 |
See footnote |
| Matthew S. Newcomb |
CHYM |
Class A Common Stock |
Gift |
-5.69% |
|
|
-22,523 |
373,597 |
18 Feb 2026 |
Direct |
| Christopher R. Britt |
CHYM |
Class A Common Stock |
Gift |
36.3% |
|
|
14,047 |
52,785 |
18 Feb 2026 |
See footnote |
| Christopher R. Britt |
CHYM |
Class A Common Stock |
Gift |
-4.74% |
|
|
-14,047 |
282,501 |
18 Feb 2026 |
Direct |
| Ryan A. King |
CHYM |
Class A Common Stock |
Gift |
31.8% |
|
|
7,147 |
29,622 |
18 Feb 2026 |
See footnote |
| Ryan A. King |
CHYM |
Class A Common Stock |
Gift |
-4.86% |
|
|
-7,147 |
140,001 |
18 Feb 2026 |
Direct |
| Adam B. Frankel |
CHYM |
Class A Common Stock |
Tax liability |
-4.2% |
|
|
-9,187 |
209,662 |
17 Feb 2026 |
Direct |
| Amine Asmerom |
CHYM |
Class A Common Stock |
Tax liability |
-4.93% |
|
|
-10,957 |
211,213 |
17 Feb 2026 |
Direct |
| Troughton Mark T. |
CHYM |
Class A Common Stock |
Tax liability |
-0.74% |
|
|
-20,037 |
2,679,727 |
17 Feb 2026 |
Direct |
| Matthew S. Newcomb |
CHYM |
Class A Common Stock |
Tax liability |
-5.71% |
|
|
-23,993 |
396,120 |
17 Feb 2026 |
Direct |
| Christopher R. Britt |
CHYM |
Class A Common Stock |
Tax liability |
-3.1% |
|
|
-9,494 |
296,548 |
17 Feb 2026 |
Direct |
| Ryan A. King |
CHYM |
Class A Common Stock |
Tax liability |
-2.98% |
|
|
-4,519 |
147,148 |
17 Feb 2026 |
Direct |
| James Feuille |
CHYM |
Class A Common Stock |
Award |
64.7% |
|
|
4,934 |
12,562 |
15 Jan 2026 |
Direct |
| James J. Dunne III |
|
Class A Common Stock |
Award |
4.07% |
|
|
2,902 |
74,197 |
15 Jan 2026 |
Direct |
| Christopher R. Britt |
|
Class A Common Stock |
Sale |
-100% |
$1,402,825 |
$28.06 |
-50,000 |
0 |
09 Jan 2026 |
See footnote |
| Christopher R. Britt |
|
Class A Common Stock |
Conversion of derivative security |
|
|
|
50,000 |
50,000 |
09 Jan 2026 |
See footnote |
| Christopher R. Britt |
|
Class B Common Stock |
Conversion of derivative security |
-15% |
|
|
-50,000 |
283,000 |
09 Jan 2026 |
See footnote |
| Matthew S. Newcomb |
|
Class A Common Stock |
Sale |
-0.44% |
$280,109 |
$28.01 |
-10,000 |
2,240,798 |
09 Jan 2026 |
See footnote |
| Adam B. Frankel |
|
Class A Common Stock |
Sale |
-0.23% |
$14,000 |
$28.00 |
-500 |
218,849 |
09 Jan 2026 |
Direct |
| Adam B. Frankel |
|
Class A Common Stock |
Options Exercise |
0.23% |
|
|
500 |
219,349 |
09 Jan 2026 |
Direct |
| Adam B. Frankel |
|
Employee Stock Option (Right to buy) |
Options Exercise |
-0.18% |
|
|
-500 |
273,567 |
09 Jan 2026 |
Direct |
| Adam B. Frankel |
|
Class A Common Stock |
Options Exercise |
4.46% |
|
|
9,349 |
218,849 |
08 Jan 2026 |
Direct |
| Adam B. Frankel |
|
Class A Common Stock |
Sale |
-2.05% |
$119,571 |
$27.29 |
-4,382 |
209,500 |
08 Jan 2026 |
Direct |
| Adam B. Frankel |
|
Employee Stock Option (Right to buy) |
Options Exercise |
-3.3% |
|
|
-9,349 |
274,067 |
08 Jan 2026 |
Direct |
| James Feuille |
|
Class A Common Stock |
Sale |
-0.1% |
$179,424 |
$24.82 |
-7,229 |
7,037,707 |
16 Dec 2025 |
By Crosslink Crossover Fund VI, L.P. |
| Troughton Mark T. |
|
Class A Common Stock |
Tax liability |
-0.35% |
|
|
-9,522 |
2,699,764 |
15 Dec 2025 |
Direct |
| James Feuille |
|
Class A Common Stock |
Sale |
-2.44% |
$4,778,332 |
$27.12 |
-176,168 |
7,044,936 |
11 Dec 2025 |
By Crosslink Crossover Fund VI, L.P. |
| Adam B. Frankel |
|
Class A Common Stock |
Sale |
-0.2% |
$13,500 |
$27.00 |
-500 |
252,416 |
11 Dec 2025 |
Direct |
| Adam B. Frankel |
|
Class A Common Stock |
Options Exercise |
0.2% |
|
|
500 |
252,916 |
11 Dec 2025 |
Direct |
| Adam B. Frankel |
|
Employee Stock Option (Right to buy) |
Options Exercise |
-0.14% |
|
|
-500 |
360,500 |
11 Dec 2025 |
Direct |
| Adam B. Frankel |
|
Class A Common Stock |
Sale |
-0.39% |
$25,500 |
$25.50 |
-1,000 |
252,416 |
10 Dec 2025 |
Direct |
| Adam B. Frankel |
|
Class A Common Stock |
Options Exercise |
1.2% |
|
|
3,000 |
252,916 |
10 Dec 2025 |
Direct |
| Adam B. Frankel |
|
Employee Stock Option (Right to buy) |
Options Exercise |
-0.82% |
|
|
-3,000 |
361,000 |
10 Dec 2025 |
Direct |
| Troughton Mark T. |
|
Class A Common Stock |
Award |
3.04% |
|
|
80,000 |
2,709,286 |
08 Dec 2025 |
Direct |
| Troughton Mark T. |
|
Employee Stock Option (Right to buy) |
Award |
|
|
|
160,000 |
160,000 |
08 Dec 2025 |
Direct |
| Adam B. Frankel |
|
Class A Common Stock |
Options Exercise |
2.45% |
|
|
6,000 |
250,416 |
08 Dec 2025 |
Direct |
| Adam B. Frankel |
|
Class A Common Stock |
Sale |
-2.69% |
$161,175 |
$23.84 |
-6,760 |
244,416 |
08 Dec 2025 |
Direct |
| Adam B. Frankel |
|
Employee Stock Option (Right to buy) |
Options Exercise |
-1.62% |
|
|
-6,000 |
364,000 |
08 Dec 2025 |
Direct |
| Amine Asmerom |
|
Class A Common Stock |
Sale |
-13.5% |
$702,603 |
$20.31 |
-34,589 |
222,170 |
28 Nov 2025 |
Direct |